GlassScriptPhysician profile
David Y Patten
NPI 1841463114
$12,155.83
in general payments reported to CMS, 2019-2025
33 companies · $2,305 in 2025
The $2,305 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,767 · 2020: $962 · 2021: $737 · 2022: $2,096 · 2023: $2,277 · 2024: $2,011 · 2025: $2,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,513 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,513.01 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,001.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,436.15 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,085.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $884.27 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $801.39 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $610.66 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $414.97 | 2019-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $329.84 | 2019-2024 | Yupelri |
| Amgen INC. | $265.81 | 2022-2025 | Tezspire |
| Insmed, INC. | $256.01 | 2019-2025 | Arikayce |
| Baxter Healthcare | $237.97 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Sunovion Pharmaceuticals INC. | $189.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $189.72 | 2019-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $175.15 | 2021-2023 | |
| United Therapeutics Corporation | $164.71 | 2019-2024 | Tyvaso |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $140.65 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $136.47 | 2019-2024 | Nuzyra |
| Verona Pharma, INC. | $117.66 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $116.44 | 2025 | Yupelri |
| Vifor Pharma, INC. | $95.02 | 2025 | Veltassa |
| Genentech USA, INC. | $86.15 | 2019 | |
| Circassia INC. | $73.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.11 | 2024-2025 | Glassia |
| Inogen, INC. | $57.40 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Teva Pharmaceuticals USA, INC. | $35.46 | 2019-2020 | |
| Ethicon INC. | $35.11 | 2021 | |
| Philips North America LLC | $29.71 | 2023-2024 | (Ak6) Vest Therapy |
| Gilead Sciences, INC. | $25.81 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.78 | 2023 | Acthar |
| Pfizer INC. | $20.24 | 2023 | |
| Liquidia Technologies, INC. | $20.09 | 2025 | Yutrepia |
| Advanced Respiratory, INC | $16.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.